Followers | 8 |
Posts | 554 |
Boards Moderated | 0 |
Alias Born | 08/03/2017 |
![](https://investorshub.advfn.com/uicon/626980.png?cb=1502472902)
Tuesday, December 10, 2019 7:14:57 PM
12/10/19, 1:37 PM
Equillium Inc. (EQ) shares rose 16% to $4.68 after the company said the U.S. Food and Drug Administration has granted fast-track designation for itolizumab for the treatment of lupus nephritis.
Equillium said it initiated the Equalise Phase 1b study of itolizumab in patients with lupus and lupus nephritis in September.
The biotechnology company said the trial will be assessing the opportunity to take a personalized medicine approach to identify patients where the CD6-ALCAM pathway may be a dominant driver of the disease. There are currently no FDA- approved therapies for lupus nephritis, Equillium said.
Always do your own DD. Any opinions expressed by me are in my opinion and shouldn't be taken as investment advice. Words to live by: "A Fool and His Money are Soon Parted" - Thomas Tusser
Recent EQ News
- Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit • Business Wire • 09/10/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/04/2024 12:00:00 PM
- Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference • Business Wire • 08/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:26 PM
- Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights • Business Wire • 08/08/2024 08:01:00 PM
- Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease • Business Wire • 08/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 06:08:53 PM
- Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance • Business Wire • 07/18/2024 05:57:00 PM
- Equillium to Participate in Upcoming Investor Conferences • Business Wire • 07/02/2024 12:00:00 PM
- Equillium to be included in the Russell Microcap® Index • Business Wire • 06/12/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 12:00:55 PM
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata • Business Wire • 06/04/2024 12:00:00 PM
- Equillium to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:56:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:00:15 PM
- Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease • Business Wire • 05/14/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:11:09 PM
- Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights • Business Wire • 05/09/2024 08:01:00 PM
- Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists • Business Wire • 05/07/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 12:00:00 PM
- Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis • Business Wire • 04/01/2024 12:00:00 PM
- Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights • Business Wire • 03/25/2024 08:01:00 PM
- Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference • Business Wire • 03/22/2024 12:00:00 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM